Renton Hollings reported option exercise involving 5,000 shares of ANAPTYSBIO, INC at $18.03 for $90.2k on Oct 1, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Director
DIR
Filed Oct 2, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$90,150Shares × reported price
Shares traded
5,000Common Stock
Price per share
$18.03Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
15,995Direct
Trade date
Oct 1, 2026Option exercise
Filed
Oct 2, 2026, 5:47 PM ET1-day reporting delay
Accession
0001187333-26-000004Code M · Transaction 235586
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Oct 1, 2026Sell5,000$49.87−$249,371.50Trade 235587
Oct 1, 2026Option exercise5,000$0.00$0Trade 235588
3 transaction rows in this filing. Joint filers share the same rows.

ANAB price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ANAB · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +14%1w ago +6.5%1d ago +3.6%
Returns since7d −5.3%30d −0.5%90d180d1y

Footnotes in full

F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.435 to $50.37 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The stock option is fully vested and exercisable. F4: In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 92,320 shares of common stock, which options vest according to their terms.